Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) (OptIMize)

9 november 2026 uppdaterad av: Geron Corporation

A Randomized, Single-Blind, Multicenter Phase 4 Trial Evaluating Two Imetelstat Doses in Participants With Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS)

This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic visit every four weeks. Participants won't be told which dose they receive, but their study doctors and the study sponsor will know.

The main goal is to learn whether the lower dose can be safer while still reducing transfusion needs.

Blood tests will be done often, especially early in treatment. If blood counts fall too much or other serious side effects occur, treatment may be delayed, lowered, or stopped. Participants in the lower-dose group who have no clear benefit after at least six treatment cycles may be allowed to move to the higher dose if they meet safety requirements. Study treatment can continue until the disease gets worse, side effects become too severe, patient chooses to stop, or the study ends. Study visits include blood tests, physical exams, vital signs, reviews of transfusions and side effects, and sometimes cardiac or bone marrow tests. Investigators will also collect extra blood samples to study imetelstat pharmacokinetic and how it affects blood cells and MDS-related genes.

Taking part is voluntary. Participants may leave the study at any time.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Man or woman greater than or equal to (≥) 18 years of age
  • Diagnosis of MDS according to World Health Organization (WHO) 2016 classification confirmed by bone marrow aspirate and biopsy within 6 months prior to randomization that meets revised IPSS-R classification of very low, low, or intermediate risk disease
  • RBC transfusion dependent, defined as requiring at least 4 RBC units transfused over an 8-week period during the 16 weeks prior to randomization; pre-transfusion Hgb should be ≤ 9.0 g/dL to count towards the 4 units total.
  • Relapsed/refractory to, or ineligible for, erythropoiesis-stimulating agent (ESA) (EPO levels > 500 or per local guidelines); or Relapsed/refractory to, or ineligible for, erythroid maturation agent (EMA) (such as luspatercept) and has an endogenous serum EPO level >200 mU/mL at time of screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

Exclusion Criteria:

  • Participant has known allergies, hypersensitivity, or intolerance to imetelstat or its excipients
  • Prior treatment with imetelstat
  • Participant has received an experimental or investigational drug or used an invasive investigational medical device within 30 days of randomization
  • Has received corticosteroids greater than (>) 30 milligram per day (mg/day) prednisone or equivalent within 4 weeks prior to randomization, or growth factor treatment for a 7-day period or 7 half-lives of growth factor used prior to randomization, whichever is longer.
  • Has received ESA or EMA therapy within 4 weeks prior to randomization (8 weeks for long-acting ESAs) or any chemotherapy, immunomodulatory or immunosuppressive therapy, within 4 weeks prior to randomization

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Övrig: Arm A: imetelstat 7.1 mg/kg

Participants will receive imetelstat at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

imetelstat will be given intravenously at 7.1 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Experimentell: Arm B: imetelstat 3.55 mg/kg

Participants will receive imetelstat at 3.55 mg/kg intravenous (IV) every 28days (±3 days), until disease progression or unacceptable toxicity, withdrawal of treatment or end of study.

imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of ≥ 12-week Red Blood Cell Transfusion Independence (RBC TI) with concurrent mean Hgb rise of at least 1.5 g/dL
Tidsram: Weeks 1-24

Proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of Grade 3/4 thrombocytopenia by laboratory values
Tidsram: Weeks 1-24

Proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 thrombocytopenia events by laboratory values before subsequent anticancer therapy or dose escalation if any

Weeks 1-24

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of ≥ 12 weeks RBC TI
Tidsram: Weeks 1-24

Proportion of participants without any RBC transfusion during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Weeks 1-24
Rate of ≥ 12 weeks RBC TI with concurrent mean Hgb rise of at least 1.5 g/dL
Tidsram: Up to End of Study (approximately 3.5 years)

It is defined as the proportion of participants who do not have any RBC transfusion with concurrent mean Hgb rise of at least 1.5 g/dL during any consecutive 12 weeks (84 days) at any time starting from randomization until subsequent anticancer therapy or dose escalation if any.

Up to End of Study (approximately 3.5 years)
Rate of RBC TI ≥ 8 weeks, ≥12 weeks, ≥ 16 weeks, or ≥ 24 weeks
Tidsram: Up to End of Study (approximately 3.5 years)

Proportion of participants without any RBC transfusion during any consecutive 8, 12, 16, or 24 weeks (56, 84, 112, or 168 days) respectively at any time starting from randomization until subsequent anti-cancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Duration of RBC TI Response
Tidsram: Up to End of Study (approximately 3.5 years)

Duration of RBC TI defined as the first day of the longest RBC TI period to the date of the first RBC transfusion after the TI period started.

Up to End of Study (approximately 3.5 years)
Time to RBC TI Response
Tidsram: Up to End of Study (approximately 3.5 years)

It is defined as the interval from randomization to the first day of corresponsive RBC TI response

Up to End of Study (approximately 3.5 years)
Hgb peak and rise
Tidsram: Up to End of Study (approximately 3.5 years)

Hgb peak defined as the maximum Hgb value excluding values that were within 14 days after transfusion. Hgb rise defined as the difference between the Hgb peak and the pretreatment Hgb level

Up to End of Study (approximately 3.5 years)
Rate of Hgb rise of at least 1.5 g/dL lasting ≥ 12 weeks
Tidsram: Up to End of Study (approximately 3.5 years)

Defined as the proportion of participants who had Hgb rise lasting at least 12 weeks during any consecutive 12 weeks (84 days) starting from randomization until subsequent anticancer therapy or dose escalation if any

Up to End of Study (approximately 3.5 years)
Rate of Hematologic Improvement Including Erythroid Response (HI-E) as Per International Working Group (IWG) Response Criteria 2018
Tidsram: Up to End of Study (approximately 3.5 years)

For low transfusion burden participants (who received 3 to 7 RBC units in the 16 weeks prior to trial entry): Clinically meaningful HI-E response per revised IWG 2018 is defined as 16-week RBC TI, i.e., participants without any RBC transfusion during any consecutive 16 weeks.

For high transfusion burden participants (who received ≥ 8 RBC units in the 16 weeks prior to trial entry):

  • Major HI-E response per revised IWG 2018 is defined as 16-week RBC TI.
  • Minor HI-E response per revised IWG 2018 is defined as a reduction by at least 50% of RBC units over a 16-week period compared with the 16 weeks prior to trial entry.
Up to End of Study (approximately 3.5 years)
Rate of disease progression, including AML progression
Tidsram: Up to End of Study (approximately 3.5 years)

Proportion of participants who had disease progression (or AML progression) per modified IWG 2006 criteria

Up to End of Study (approximately 3.5 years)
Rate of Grade 3/4 neutropenia by laboratory values
Tidsram: Weeks 1-24

Defined as the proportion of participants who had at least one dose of trial treatment and who had experienced Grade 3 or Grade 4 neutropenia events by laboratory values before subsequent anticancer therapy or dose escalation, if any

Weeks 1-24
Treatment Emergent Adverse Events (TEAEs)
Tidsram: Up to End of Study (approximately 3.5 years)

Incidence, severity, and type of treatment emergent adverse events (TEAEs, with a specific focus on bleeding and infection events), and other clinical laboratory values (including liver function test [LFT] abnormalities)

Up to End of Study (approximately 3.5 years)
Time to Resolution of Lab Events
Tidsram: Up to End of Study (approximately 3.5 years)

Time to resolution of Grade ≥ 3 neutrophil and platelet counts to baseline grade after end of dosing.

Up to End of Study (approximately 3.5 years)
Assessment of Plasma concentrations of imetelstat
Tidsram: Cycles 1-6 (28 day cycles)

Concentrations of imetelstat in Plasma

Cycles 1-6 (28 day cycles)
Assessment of Cmax
Tidsram: Cycles 1-6 (28 day cycles)

Maximum Observed Plasma Concentration (Cmax)

Cycles 1-6 (28 day cycles)
Assessment of AUC
Tidsram: Cycles 1-6 (28 day cycles)

Area under the drug concentration-plasma time curve (AUC) from time zero to last measurable concentration

Cycles 1-6 (28 day cycles)
Population PK/PD Model-Predicted Rates of Grade 3/4 Thrombocytopenia, Grade 3/4 Neutropenia, and Mean ≥1.5 g/dL Hemoglobin Increase Sustained for ≥12 Weeks
Tidsram: Cycles 1-6 (28 day cycles)
Cycles 1-6 (28 day cycles)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to acute myeloid leukemia (AML) progression among participants with documented AML progression
Tidsram: Up to End of Study (approximately 3.5 years)
Up to End of Study (approximately 3.5 years)
Assessment of biomarkers
Tidsram: Cycles 1-2 (28 day cycles)

At baseline and change from baseline

Cycles 1-2 (28 day cycles)
Assessment of Mutation status
Tidsram: Up to End of Study (approximately 3.5 years)

At baseline and change from baseline including at the time of suspected progression

Up to End of Study (approximately 3.5 years)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Joseph E Eid, MD, Geron Corporation

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 mars 2027

Primärt slutförande (Beräknad)

1 juli 2030

Avslutad studie (Beräknad)

1 januari 2031

Studieregistreringsdatum

Först inskickad

3 november 2026

Först inskickad som uppfyllde QC-kriterierna

9 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • MDS4001

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .